More News! 17 Oct 2018 The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech? AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors are already taking advantage of it. Humira is an antibody… October 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 26 Mar 2018 Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been… March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2021 AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research …with targeting tau. Their anti-tau antibody semorinemab yielded both positive and negative results in a phase II trial in people with Alzheimer’s disease. According to one established measure of patient… September 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Jan 2024 Eight newly approved drugs that could become blockbusters in 2024 …make it on the list, TALVEY is a humanized monoclonal antibody to target multiple myeloma. It has been granted accelerated approval by the FDA to those patients who have received… January 22, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was… December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2020 Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost …have some possible drawbacks. Antibody responses can decline quickly if not backed up by T helper cells, also known as ‘memory’ cells, and it’s possible that a weak antibody response… June 18, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2018 UK Biotech Wins Major Grant to Manage Chronic Pain With Antibodies …a grant of £556K (€633K) from Innovate UK to develop its antibody platform, KnotBody, for therapeutic applications in chronic pain management. Iontas’ antibody approach could provide an alternative to opioids,… May 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 CatalYm raises €50M to boost solid tumors trial …GDFATHER-2 trial (GDF-15 antibody-mediated human effector cell relocation phase 2). The study evaluates visugromab in combination with an anti-PD1 antibody in patients with advanced solid tumors that are relapsed/refractory to… November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Dec 2018 Looking Back on 2018: Our 10 Most Popular Interviews …The company has a number of candidate drugs in its pipeline targeting various cancers and inflammatory diseases. Its current lead candidate is a monoclonal antibody targeting the antigen CD19. Morphosys… December 24, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 19 Jun 2017 Discussing the Virtual Biotech Model with XO1 Co-Founder Trevor Baglin …A patient presented at my hospital with what’s called a paraprotein, which is sort of a rogue antibody produced by the aging immune system. This antibody targeted exosite 1 of… June 19, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Apr 2018 The 5 Best-Selling European Drugs of 2017 …in 2000. Once hailed as a wonder drug, trastuzumab is a monoclonal antibody that recognizes the HER2/neu receptor that is highly expressed in about 20% of breast and gastric cancers…. April 30, 2018 - 7 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
In Depth 11 Dec 2024 Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy? …Valora’s immunotherapies look much like a conventional antibody, but with one of the usual Y-like arms replaced with a lectin domain. While the antibody domain provides precise targeting to specific… December 11, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email